No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy.

Background And Objective: Attention-deficit/hyperactivity disorder (ADHD) is the most frequent psychiatric disorder in children and adolescents and is often treated with methylphenidate (MPH), resulting in MPH exposure in more than 1% of all children in many countries. A 2005 report on cytogenetic effects in peripheral lymphocytes from 12 ADHD children treated for 3 months with MPH raised questions about its genetic toxicity and potential carcinogenicity. In 2007, we described no elevated micronucleus frequency in 21 children after 3 months of MPH-treatment; since the difference between the two studies could not be explained we now enlarged the overall sample size, and added a healthy control group, a new chronically treated group and positive control slides.

[Blood lipids and the incidence of hyperlipidemia in pilots].

The content of cholesterol and triglycerides was measured in healthy pilots. Over 1500 subjects were examined and age-related norms of the parameter were established. They were compared with published data.